Answers are grounded in this paper and cite their sources.
[reaction: see text] Replacing complex natural products with simple metal complexes could lead to a new class of metallopharmaceuticals in which the metal center plays mainly a structural role. A strategy is introduced for the creation of ruthenium complex-based protein kinase inhibitors 1 (X = CO or CH(2)), morphed out of the class of indolocarbazole inhibitors with the alkaloid staurosporine as its most prominent member.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: